Antifungal Activity of Thai Cajuput Oil and Its Effect on Efflux-Pump Gene Expression in Fluconazole-Resistant Candida albicans Clinical Isolates

Candidiasis caused by the fluconazole-resistant opportunistic pathogen Candida albicans is an intractable clinical problem that threatens immunocompromised or normal individuals. The most common mechanism of fluconazole resistance in C. albicans is the failure of cells to accumulate the drug due to increased expression of the efflux proteins encoded by the CDR1, CDR2, and MDR1 genes. Because the number of current antifungal drugs is limited, it is necessary to develop new therapeutic strategies. This study aimed to evaluate the antifungal activity of Thai Cajuput oil, its synergism with fluconazole, and its effect on efflux-pump gene expression in fluconazole-resistant C. albicans clinical isolates. Thus, we first detected the efflux-pump genes in fourteen resistant strains by PCR. The frequencies of the CDR1, CDR2, and MDR1 genes were 68.75%, 62.5%, and 87.5%, respectively, and these efflux-pump genes were distributed in three distinct patterns. Subsequently, the antifungal activity of Thai Cajuput oil was assessed by broth macrodilution and its synergism with fluconazole was evaluated by the checkerboard assay. The changes in the expression levels of CDR1, CDR2, and MDR1 after treatment with Thai Cajuput oil were analyzed by qRT-PCR. The MICs and MFCs of Thai Cajuput oil ranged from 0.31 to 1.25 μl/ml and 0.63 to 1.25 μl/ml, respectively, and its activity was defined as fungicidal activity. The MICs of the combination of Thai Cajuput oil and fluconazole were much lower than the MICs of the individual drugs. Interestingly, sub-MICs of Thai Cajuput oil significantly reduced the MDR1 expression level in resistant strains (P < 0.05). Our study suggests that Thai Cajuput oil can be used to create new potential combination therapies to combat the antifungal resistance of C. albicans.


Introduction
Candidiasis is one of the most important fungal infections caused by Candida species; these infections pose a challenging threat to human health and affect millions of individuals. More than 17 species of Candida are responsible for causing both superficial and life-threatening systemic mycoses, and of these, Candida albicans is a major fungal pathogen accounting for invasive candidiasis and is the most common cause of nosocomial infections. C. albicans is a normally dimorphic commensal organism and is part of the normal flora of healthy people. However, C. albicans can undergo a transition from a commensal to pathogenic form in immunocompromised hosts/normal individuals and function as an opportunistic pathogen. C. albicans has a unique ability to grow in a variety of morphological forms (yeast-like, hyphae, pseudohyphae, and chlamydospores), which can serve as key virulence factors. In addition, the growth of Candida biofilms on medical devices has emerged as a major challenge in hospital settings, leading to secondary fungal infections and resulting in morbidity and mortality of immunocompromised individuals (including HIV-infected patients, transplant recipients, chemotherapy patients, diabetes patients, and lowbirth-weight infants) [1,2].
With the improvements made in the healthcare system worldwide, the numbers of elderly people and immunocompromised patients have dramatically increased for several reasons (including immunosuppressive treatments, long-term catheterization, use of broad-spectrum antibiotics, and longer survival of immunologically compromised individuals), resulting in an increase in candidiasis prevalence, emergence of drug resistance, lower availability of antifungal drugs, failure of treatment, and recalcitrant infections [3,4]. In 2019, the Centers for Disease Control and Prevention (CDC) reported that C. albicans is the most common cause of bloodstream infections and that antifungal resistance is a particular problem. CDC surveillance data indicate that the proportion of Candida isolates that are resistant to fluconazole has remained fairly constant over the past 20 years [5].
Among the different antifungals available, fungistatic azoles are widely used to treat Candida infections due to their high efficacy, reduced toxicity, and low cost. e emergence of azole-resistant C. albicans strains is associated with the widespread and prolonged use of azoles, especially fluconazole (FLC) [6,7]. A common mechanism of fluconazole resistance in C. albicans is the failure of cells to accumulate the drug due to increased expression of certain proteins encoded by the CDR1, CDR2, and MDR1 genes. e CDR1 and CDR2 genes encode proteins that belong to the superfamily of ATP-binding cassette (ABC) transporters.
e MDR1 gene encodes a protein that belongs to the major facilitator superfamily (MFS) transporters. Overexpression of these transporters plays an important role in fluconazole resistance in C. albicans due to increased fluconazole efflux [8]. Several studies have demonstrated enhanced susceptibility of C. albicans to fluconazole as a result of the disruption of the CDR1, CDR2, and MDR1 genes [9,10]. erefore, there is a constant demand for the development of a new generation of antifungal agents with superior antifungal properties and minimal host toxicity. e use of natural products and supplements has increased around the world, and scientists have been interested in studying plant products as antimicrobial or antifungal agents [11]. In the present study, we investigated ai Cajuput oil from Melaleuca cajuputi Powell. (Cajuput tree), which belongs to the Myrtaceae family and exclusively grows in Southern and Eastern ailand. Myrtaceae is one of the most important essential oil-producing families and has diverse bioactivities, such as antibacterial, antifungal, antioxidant, insecticidal, and antiviral activities. Cajuput oil from M. cajuputi has been used in medicine since the eighteenth century as an antiseptic agent, and its effect is comparable to that of tea tree oil from M. alternifolia [12]. At a concentration of 0.4-0.6%, Cajuput oil inhibits the growth of yeast, such as C. albicans, C. vaginalis, and C. glabrata, and mold, such as Aspergillus niger and Penicillium notatum [13,14]. ese findings support the theory that ai Cajuput oil may inhibit the growth of C. albicans and reduce the expression of genes that play an important role in fluconazole resistance in C. albicans.
In this study, we first investigated efflux-pump genes (CDR1, CDR2, and MDR1) in fluconazole-resistant C. albicans clinical isolates and evaluated the in vitro antifungal activity of ai Cajuput oil against resistant strains. In addition, we performed a checkerboard assay to investigate the antifungal effects of ai Cajuput oil combined with FLC against resistant strains and to identify whether the combinations could also reverse one of the common resistance mechanisms of increased drug efflux pumps. We conducted qRT-PCR to assess the effect of ai Cajuput oil on efflux-pump gene expression. e explanation of such mechanisms could help in the development of new therapeutic strategies, new alternative therapies, and the subsequent reversion of antifungal resistance in Candida species.

Strains, Media, and Growth
Conditions. Sixteen FLCresistant C. albicans clinical strains and C. albicans ATCC 90028 were used in this study. All isolates originated from the collection of the Department of Microbiology, Faculty of Science, Burapha University, Chonburi Province, ailand. Clinical strains were isolated from sputum and urine of hospitalized patients with mycoses in Somdej Phra Boromma Ratchathewi Na Si Racha Hospital, Chonburi Province, ailand. e isolates were periodically identified by phenotypic techniques (microscopic morphology and macroscopic morphology on Sabouraud dextrose agar and chromogenic Candida agar) and confirmed by conventional PCR assay. e strains were maintained in 30% glycerol at −80°C and subcultured at least twice on Sabouraud dextrose agar (HiMedia Laboratories, India) at 35°C. eir FLC susceptibilities were determined by the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) documents M27-A3 [15] and M60 [16] with C. albicans ATCC 90028 as the quality control strain. FLC was purchased from Sigma-Aldrich, US. e stock solution of FLC was prepared according to the manufacturer's instructions. RPMI-1640 (Gibco, Carlsbad, CA) buffered with MOPS (AppliChem GmbH, Germany) and supplemented with 0.2% glucose was used as the diluent medium for drug and strains.

Plant Material and Essential Oil Extraction.
Leaves and twigs of Melaleuca cajuputi Powell (Cajuput tree) were collected from the Community Forest in a Chang District ( e Chaipattana Foundation), Chanthaburi Province, ailand, in February 2018. Fresh leaves and twigs were harvested at random from 15-20 trees in a forest. After the natural drying of samples, 6050 g of samples was collected. Essential oils were extracted by hydrodistillation [17]. Oil was extracted as follows: an extraction temperature of 65-70°C and an extraction time of 48-72 h. e resultant yield of oil was 0.35%. Oil was analyzed by gas chromatography-mass spectrometry (GC-MS), and the six major constituents were 1,8-naphthyridine derivatives (10.46%), alpha-pyrone (10.11%), terpinolene (9.26%), gamma-terpinene (8.00%), beta-caryophyllene (6.36%), and beta-elemene (5.09%), defined as a component present at 5% or greater of the total composition. However, the oil displayed similar major components to some studies of Melaleuca cajuputi Powell essential oil from pure leaves were grown in different parts of ailand, but differences in their quantity [18][19][20]. It was preserved at 4°C in a dark brown vial in the dark until further analysis [21]. e extracted oil should have been dissolved into 100% dimethyl sulfoxide (DMSO) to continue all the experiments conducted in this study, following which they were serial diluted in a test medium to reach the concentrations to be tested. e final concentration of DMSO in the assays did not exceed 1%, which did not affect fungal growth [22].

DNA Extraction and Amplification.
To screen the effluxpump genes (CDR1, CDR2, and MDR1) among resistant strains, genomic DNA was extracted from sixteen resistant strains using organic extraction (phenol: chloroform) as described by Javadi et al. [23] with modifications. Briefly, the cell suspension (10 7 cells/ml) was lysed in lysis buffer combined with a freeze-thaw process, treated with RNase A (Invitrogen ™ , ermo Fisher Scientific, Inc., US) to inactivate cellular RNase, treated with phenol/chloroform/isoamyl alcohol (Research Organics, Inc., USA) to separate gDNA from cell debris, precipitated with ethanol and eluted in TE buffer. After extraction, DNA was quantified using a NanoDrop One C ( ermo Fisher Scientific Inc., US). e obtained DNA samples were subjected to PCR amplification. PCR was prepared in a total volume of 20 μl, which included 10 ng of DNA template, 1x FIREPol ® master mix (FIREPol® DNA polymerase, 1x reaction buffer B, 2.5 mM MgCl 2 , 200 µM dNTPs) and gene-specific primers (LGC, Biosearch Technologies, Inc., listed in Table 1). Amplification was carried out in a Mastercycler® nexus (Eppendorf AG, Germany) using conditions modified from Ricardo et al. [10]. Reactions were performed as follows: initial denaturation at 95°C for 4 mins, followed by 35 cycles of denaturation at 95°C for 20 secs, annealing at 55-58°C for 1 min (Table 1) and extension at 72°C for 20 secs, and a final extension at 72°C for 4 mins. e appropriate positive control and no template control were included in each experiment. e amplicons were separated by electrophoresis on a 2% agarose gel, analyzed and visualized under blue light using an Omega Fluor ™ Plus (Gel Company, Inc., USA).

Antifungal Activity of Essential Oil.
e broth macrodilution method was used to determine the minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of the ai Cajuput oil against resistant strains according to the CLSI documents M27-A3 [15] and M60 [16] with C. albicans ATCC 90028 as the quality control strain. In brief, cell suspensions of sixteen resistant strains (0.5-2.5 × 10 3 cells/ml) in an RPMI-1640 medium (w/MOPS + 0.2% glucose) were added to serial tubes cultured with different concentrations of ai Cajuput oil and were then incubated at 37°C for 48 h. e final concentrations of ai Cajuput oil were two-fold serially diluted in a test medium ranging from 0.04 to 5 μl/mL (0.04, 0.08, 0.16, 0.31, 0.63, 1.25, 2.5, and 5 μl/ml), and the final concentration of DMSO did not exceed 1%. e growth control contained yeast cells and broth medium with no essential oil. e solvent control contained yeast cells and a broth medium with 1% DMSO. e purity control contained only a broth medium. To decide and confirm the primary decision regarding the MIC and MFC of ai Cajuput oil, 10 μl of broth from the first tube that showed no clear growth and the two successive clear tubes were dropped onto SDA plates. en, the inoculated plates were incubated at 37°C for 24 h. e MIC was defined as the lowest concentration of ai Cajuput oil that inhibited visible growth of C. albicans isolates within the tube. On the other hand, the MFC was defined as the lowest concentration of ai Cajuput oil that completely inhibited the growth of C. albicans isolates on SDA plates [24]. e experiment was repeated three times, and the average MICs and MFCs were recorded. e MFC/ MIC ratio was calculated to determine antifungal activity, and a substance was defined as having fungistatic activity when the MFC/MIC ratio ≥4 and as having fungicidal activity when the MFC/MIC ratio <4 [25].

Checkerboard Synergy Analysis.
e effect of FLC combined with ai Cajuput oil was evaluated using the checkerboard method with slight modifications [26]. Concisely, four resistant strains (S7/1, U6/2, U15/1, and U8/1) that showed different efflux-pump gene patterns were used, and cell suspensions of these strains (0.5-2.5 × 10 3 cells/ml) in RPMI-1640 medium (w/MOPS + 0.2% glucose) were added to a 96-well plate cultured with different concentrations of FLC + ai Cajuput oil and were then incubated at 37°C for 48 h. e final concentrations of FLC were twofold serially diluted in a test medium ranging from 0.125 to 64 mg/mL (0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, and 64 μg/mL), the final concentration of ai Cajuput oil was two-fold serially diluted in a test medium ranging from 0.04 to 1.25 μl/ mL (0.04, 0.08, 0.16, 0.31, 0.63, and 1.25 μl/mL), and the final concentration of DMSO did not exceed 1%. e growth control contained yeast cells and a broth medium with no drug and essential oil. e solvent control contained yeast cells and a broth medium with 1% DMSO. e purity control contained only a broth medium. e experiment was repeated three times, and drug interactions were interpreted by the fractional inhibitory concentration index (FICI) model. e FICI was calculated as the sum of the FICs of either drug (MIC FLC + Cajuput oil /MIC FLC + MIC Cajuput oil + FLC /MIC Cajuput oil ). An FICI ≤0.5 represents synergistic activity; >0.5 and ≤1 additive activity; >1 and ≤4 indifferent activity; and >4 antagonistic activity [27].

Gene Expression Analysis.
To compare the changes in the expression of the efflux-pump genes (CDR1, CDR2, and MDR1), total RNA was extracted from resistant strains before and after treatment with ai Cajuput oil. Four resistant strains (S7/1, U6/2, U15/1, and U8/1) that showed different efflux-pump gene patterns were selected and incubated in SDB at 37°C for 24 h with continuous shaking at 240 rpm. e cell suspensions (10 7 cells/ml) were treated with ½MIC, ¼MIC, and ⅛MIC of ai Cajuput oil and 1% International Journal of Microbiology DMSO as solvent control in SDB at 37°C for 90 min with continuous shaking at 240 rpm. Cultures without ai Cajuput oil served as the untreated. Cells were then harvested for RNA extraction, and total RNA was isolated using TRIsure ™ reagent (Bioline, UK) following the manufacturer's instructions. e RNA samples were quantified using a NanoDrop One C ( ermo Fisher Scientific Inc., US).
One-step real-time reverse transcription PCR (qRT-PCR) was performed using the One-step BrightGreen qRT-PCR Kit (Applied Biological Materials, Inc., Canada) following the manufacturer's instructions. RT-PCR was performed in a total volume of 10 μl, which included 5 ng of total RNA, 1X BrightGreen qPCR master mix, 1X qRT-PCR enzyme mix, and gene-specific primers (LGC, Biosearch Technologies, Inc., listed in Table 1). Amplifications were carried out in the CFX96 Touch ™ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., USA). e following cycling protocol was used: cDNA synthesis at 42°C for 15 mins, predenaturation at 95°C for 4 mins, followed by 35 cycles of denaturation at 95°C for 20 secs, and annealing/elongation at 55-58°C for 1 min (Table 1). e appropriate positive control and no template control were included in each experiment. To verify the specificity of the amplicon, the products were evaluated via melting point analysis conducted directly after amplification to determine the dissociation of the PCR products from 65°C to 95°C. e threshold cycle (Ct) values were automatically determined by CFX Manager ™ Software (Bio-Rad Laboratories Inc., USA) using the default parameters. e Ct values are defined as the cycle number when the fluorescence signal of a PCR product can be detected above the background signal. e Ct value is a relative measure of the concentration of target in the PCR reaction.
e expression levels of the efflux-pump genes (CDR1, CDR2, and MDR1) were evaluated using the 2 −∆∆Ct method, where cycle threshold (Ct) is the abbreviation for quantification cycle, formerly known as cycle quantification (Cq). e qRT-PCR reactions were performed in duplicate, and Ct values were averaged according to the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines [28]. Essentially, all data were normalized to the ACT1 housekeeping gene as the internal reference gene and were compared to an untreated calibrator sample. e data are presented as the fold change of gene expression.

Statistical Analysis.
e broth macrodilution method and the checkerboard assay were performed in three independent experiments, and the results are reported relative to the control. Statistical analyses were performed using the statistical package for social sciences (SPSS), version 22.0 release for Microsoft Windows (SPSS, Inc., Chicago). e expression levels of the efflux genes before and after treatment were compared using the paired t-test, in which a p value of less than 0.05 was considered statistically significant.

Efflux-Pump Gene Patterns among Resistant Strains.
According to efflux-pump gene screening among sixteen resistant strains by PCR, efflux-pump genes were detected in fourteen resistant strains (87.5%) but not in two resistant strains (12.5%). e PCR products of the CDR1, CDR2, and MDR1 genes after separation by electrophoresis on an agarose gel are shown in Figure 1. e presence of the MDR1 gene showed the highest frequency among the fourteen resistant strains. e frequencies of the CDR1, CDR2, and MDR1 genes were 68.75%, 62.5%, and 87.5%, respectively. e efflux-pump genes were distributed in three distinct patterns: pattern A was CDR1-, CDR2-, and MDR1-positive (n � 10); pattern B was CDR1-and MDR1-positive (n � 1); and pattern C was only MDR1-positive (n � 3), as presented in Table 2.

Antifungal Activity of ai Cajuput Oil.
e antifungal activity of ai Cajuput oil against the fourteen resistant strains was evaluated using the broth macrodilution method. e mean of three independent experiments was determined and reported as MICs, MFCs, and MFC/MIC ratios in Table 2. ai Cajuput oil inhibited the growth of all resistant strains. e MICs and MFCs ranged from 0.31 to 1.25 μl/ml and 0.63 to 1.25 μl/ml, respectively. According to the MFC/ MIC ratio calculation, the ratios were within the range of 1 to 2, and the antifungal activity of ai Cajuput oil was defined as fungicidal activity.

Efflux-Pump Genes Expression.
To investigate the effect of ai Cajuput oil on four resistant strains with different efflux-pump gene patterns, the expression levels of the efflux-pump genes were evaluated using qRT-PCR. Quantification data for all the genes were normalized to the reference gene and compared to the untreated control. ere were no primer dimers or nonspecific amplification products according to the melting curves and melting peaks of all the tested genes. e relative fold changes in CDR1, CDR2, and MDR1 gene expression in the S7/1, U6/2, U15/1, and U8/1 strains are shown in Figures 2-5, respectively. For all tested strains, there was no significant difference in the CDR1 and CDR2 expression levels among treatments (p > 0.05); however, the MDR1 expression levels among treatments with ½MIC, ¼MIC, and ⅛MIC of Cajuput oil decreased. Concisely, subinhibitory concentrations of Cajuput oil (½MIC) only significantly reduced the MDR1 expression level in resistant strains (p > 0.05).

Discussion
Fluconazole-resistant C. albicans is responsible for the most prevalent nosocomial fungal infections and has resulted in many clinical treatment failures. Different mechanisms may be expressed, allowing organisms to elude the effects of antifungals. One of the most important molecular mechanisms causing azole resistance in C. albicans is the increased efflux of a drug, mostly mediated by the ATP-binding cassette (ABC) and major facilitator superfamily (MFS) transporters [29]. e emergence of fungal resistance to antifungal agents has been rapidly increasing, but the rate of new antifungal production is insufficient to meet the current need [30].
is situation indicates the importance of developing new promising antifungal agents or exciting the future of antifungal therapy. e goal of this study was to investigate the effect of Melaleuca cajuputi Powell ( ai Cajuput oil) on efflux-pump gene (CDR1, CDR2, and MDR1) expression in fluconazole-resistant C. albicans clinical isolates using qRT-PCR.
In this investigation, we first identified genes encoding drug efflux pumps (CDR1, CDR2, and MDR1) among sixteen resistant strains. All the efflux-pump genes were detected in fourteen of sixteen resistant strains, and the presence of the MDR1 gene showed the highest frequency among resistant strains. e frequencies of the CDR1, CDR2, and MDR1 genes were 68.75%, 62.5%, and 87.5%, respectively. Comparably, Perea et al. observed efflux-pump genes (CDR and MDR1) in 86% of all azole-resistant isolates, and overexpression of the CDR and MDR1 genes was detected in 83% and 67%, respectively, of azole-resistant isolates [8].
Many studies have confirmed that the nature of azole resistance is multifactorial, with a predominance of the overexpression of genes encoding drug efflux pumps [31][32][33].
ai Cajuput oil is obtained from leaves and twigs of Melaleuca cajuputi Powell. (Cajuput tree), which belongs to the Myrtaceae family. Although essential oils from Myrtaceae species have diverse bioactivities, reports on the antifungal activity of essential oils from M. cajuputi are limited.
e results of our study also demonstrated the strong antifungal activity of ai Cajuput oil against fourteen resistant strains that carried efflux-pump genes. e MICs and MFCs ranged from 0.31 to 1.25 μl/ml and 0.63 to 1.25 μl/ml, respectively. e antifungal activity of ai Cajuput oil was defined as fungicidal activity. Similar results have been reported the same genus in the Myrtaceae family: the MICs of M. alternifolia (tea tree oil) against FLC-resistant C. albicans clinical isolates are 2.5-5 μl/ml as described by Mondello et al. [34] and the MICs and MFCs of M. alternifolia oil against C. albicans ATCC 90028 are 2.5 μl/ml as described by Francisconi et al. [35]. However, the antifungal activity of ai Cajuput oil could be attributed to its complex mixture of biologically active compounds, which greatly differs according to the chemotype of the plant and the place from which the plant was obtained. In this work, essential oil from M. cajuputi Powell contained six important components, including 1,8-naphthyridine derivatives, alpha-pyrone, terpinolene, gamma-terpinene, beta-caryophyllene, and betaelemene. Some studies have indicated that compounds present in spices may also play a major role in their antifungal effects. Acosta et al. described that the potential antifungal activity of 1,8-naphthyridine derivatives is related to their hydrophobicity, which disrupts the membrane integrity of C. albicans and Cryptococcus neoformans cells [36]. Similarly, Pereira et al. indicated that beta-caryophyllene may be absorbed by the fungal cell membrane and act as an antifungal agent by releasing lipophilic drugs [37]. Additionally, the antifungal effects of terpinolene and gammaterpinene have been shown in another study [38]. ese findings suggest that the effect of ai Cajuput oil may be related to these components.
Regarding the synergism of ai Cajuput oil and FLC against four resistant strains that had different efflux-pump gene patterns, we found that the MICs of drug combinations 6 International Journal of Microbiology   [39]. e synergism of ai Cajuput oil and FLC suggests that essential oil may play a role in reducing drug resistance in C. albicans clinical isolates. Evaluating the expression of genes that are responsible for drug resistance in C. albicans is the most accurate method to prove this hypothesis.
According to qRT-PCR, our findings revealed that the expression levels of CDR1 and CDR2 were not significantly different among treatments (p > 0.05), while the MDR1 expression levels upon treatment with ½MIC, ¼MIC, and ⅛MIC of Cajuput oil were decreased. e subinhibitory concentrations of Cajuput oil (½MIC) only significantly reduced the MDR1 expression level in resistant strains (p < 0.05). It is known that the overexpression of the MDR1 gene is the main cause of the prevalence of FLC-resistant C. albicans, which effectively reduces the intracellular concentration of antifungal agents and ultimately makes FLC ineffective. Ahmad et al. showed that the inhibition of effluxpump genes (CDR1 and MDR1) in FLC-resistant Candida spp. by two monoterpenes is a feasible strategy to overcome clinical antifungal resistance [40]. Similarly, Morschhäuser J. demonstrated that disruption of the MDR1 gene in the C. albicans strain, in which it was strongly expressed, resulted in increased susceptibility of the mutants to several antifungal drugs [41]. e impact of this report indicates for the first time that ai Cajuput oil was identified as an inhibitor of FLCresistant C. albicans clinical isolates which reduced the expression level of the MDR1 gene. In addition, it is interesting to study further on the point of effect of ai Cajuput oil inhibits MDR1 expression by repressing transcription factors such as Mrr1. e great influence of this study indicates that ai Cajuput oil can be successfully employed as a good candidate for the inhibition of C. albicans growth and may be a potential source of natural antifungal agents to battle resistant Candida infections.

Conclusions
In summary, ai Cajuput oil is widely distributed in Eastern ailand. Leaves and twigs of M. cajuputi Powell were found to have potent antifungal activity against FLCresistant C. albicans clinical isolates. ai Cajuput oil was able to reduce the MIC of fluconazole and reduce the expression level of MDR1, an important gene that plays a role in resistance to azole drugs in C. albicans. ese results are of considerable importance due to the increasing resistance of emerging fungal species to available drugs used to treat a variety of fungal infections and for the exploration of potential alternative therapeutic sources for multidrug resistant therapy.

Data Availability
Data used to support the findings of this study are included within the article and also available from the corresponding author upon request.

Ethical Approval
is study was approved by the Institutional Review Board and the Institutional Biosafety Committee of Burapha University, Chonburi, ailand.